Brief: Gentian Diagnostics Q3 Sales Up 28% Y/Y
23/10/2025 07:19
Oct 23 (Reuters) - Gentian Diagnostics ASA GENT.OL: Q3 SALES OF NOK 41.8 MILLION, UP 28% VERSUS 3Q 2024 Q3 EBITDA OF NOK 8.4 MILLION VERSUS NOK 5.0 MILLION IN 3Q 2024 Q3 GROSS MARGIN OF 56% VERSUS 52% IN 3Q 2024 Further company coverage: GENT.OL (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Gentian Diagnostics ASA
See all newsBrief: Essange Reagents And Gentian Diagnostics Announce Collaboration Agreement
Brief: Gentian Diagnostics: Vatne Capital Reduces Indirect Ownership
Brief: Gentian Diagnostics Renews Long-Term Partnership With Bühlmann Laboratories
Brief: Gentian Diagnostics Q4 EBITDA NOK 10.5 Million
Brief: Gentian Diagnostics Enters Exclusive Agreement With Global Diagnostics Company